A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer, Malignancy

In brief

The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.

Key facts

Study ID

NCT00879554

Run by

Pfizer

People needed

40

Starts

2007-02-01

Expected to finish

2010-11-01

Last updated by the study team

2010-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed advanced solid tumors unresponsive to currently available therapies, or for which there is no standard therapy.
• Adequate coagulation, liver and renal function.
• Candidate for DCE-MRI evaluation.
• ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.

You may not qualify if…

• Evidence of bleeding problems.
• Uncontrolled hypertension.
• Certain gastrointestinal problems including fistula and abscess.
• Patients with primary brain cancer.

Where it is running

• Pfizer Investigational Site — Scottsdale, Arizona, United States
• Pfizer Investigational Site — Santa Monica, California, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.